CTI BioPharma Investors

CTI BioPharma is a company that focuses on developing and selling cancer treatment products. One of its main products in development is Pixantrone, which is currently in phase III trials and is intended for non-Hodgkin's lymphoma.
Headquarters:
Seattle, Washington, United States
Employee Number:
11-50
Industry:
PharmTech
Investor Type:
Funds of Funds